For research purposes only. This content is intended for scientific and educational reference. Not intended for human use or as medical advice.
Introduction
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide consisting of 15 amino acids (sequence: GEPPPGKPADDAGLV) derived from a protein found in human gastric juice. With a molecular weight of approximately 1419.5 Da, BPC-157 has been the subject of extensive preclinical research, particularly in the areas of tissue repair, gastrointestinal function, and neuroprotection.
Unlike many investigational peptides currently in active clinical development β such as Retatrutide (LY3437943), which is being studied for metabolic applications β BPC-157 research has focused primarily on regenerative and cytoprotective mechanisms in animal models. The compound has accumulated one of the largest bodies of preclinical literature of any research peptide in its class.
Mechanism of Action
BPC-157’s biological activity in preclinical models has been associated with several distinct molecular pathways, often acting simultaneously to produce tissue-protective effects.
VEGF Pathway and Angiogenesis
One of the most studied mechanisms of BPC-157 involves its interaction with the vascular endothelial growth factor (VEGF) system. Preclinical research suggests BPC-157 may upregulate VEGF expression and promote angiogenesis β the formation of new blood vessels β in injured tissue. Enhanced vascular supply to damaged tissue is considered a key component of the accelerated healing responses observed in animal models.
Nitric Oxide (NO) System Modulation
BPC-157 has been shown in multiple rodent studies to interact with the nitric oxide system, influencing both NO synthesis and signaling. The NO pathway plays a central role in vascular tone, inflammation regulation, and cytoprotection. Researchers have proposed that BPC-157’s effects on the NO system may account for some of its observed gastrointestinal and vascular protective properties.
FAK-Paxillin Pathway
Research has identified the focal adhesion kinase (FAK) and paxillin signaling pathway as a potential mediator of BPC-157’s effects on cell migration and tissue repair. FAK-paxillin signaling is involved in cytoskeletal organization and cell movement β processes critical to wound closure and regenerative healing.
Growth Hormone Receptor Interaction
Preclinical studies have suggested that BPC-157 may interact with growth hormone receptor signaling pathways, potentially contributing to its observed effects on tendon and muscle tissue in rodent models. This interaction is distinct from direct growth hormone secretagogue activity and remains an area of ongoing investigation.
Cytokine Modulation
BPC-157 has demonstrated modulatory effects on pro-inflammatory cytokine expression in multiple animal models. Reductions in TNF-Ξ±, IL-6, and other inflammatory markers have been observed in rodent studies of gut inflammation and tissue injury, suggesting a potential anti-inflammatory mechanism of action.
Key Areas of Preclinical Research
Gastrointestinal Research
BPC-157 was originally identified through research on gastric juice proteins, and gastrointestinal applications represent the most extensively studied area. Rodent studies have examined BPC-157 in models of:
- Inflammatory bowel disease (IBD)
- Gastric ulceration
- Intestinal anastomosis healing
- Esophageal lesions
- Short bowel syndrome models
Researcher Predrag Sikiric and colleagues at the University of Zagreb have published extensively on BPC-157’s effects in gastrointestinal models, representing the largest single body of BPC-157 preclinical literature.
Musculoskeletal and Connective Tissue Research
BPC-157 has been studied in numerous rodent models of tendon, ligament, muscle, and bone injury. Studies have examined:
- Transected Achilles tendon repair models
- Ligament healing following surgical transection
- Muscle crush injury recovery
- Bone defect healing models
These studies have generally reported accelerated healing timescales and improved tissue organization in BPC-157-treated animals compared to controls, though the precise mechanisms driving these effects continue to be investigated.
Neurological Research
A growing body of preclinical literature has examined BPC-157 in models of neurological injury and dysfunction, including:
- Traumatic brain injury models
- Spinal cord injury recovery
- Dopaminergic system studies (relevant to Parkinson’s disease models)
- Peripheral nerve regeneration
Researchers have proposed neuroprotective and neuroregenerative mechanisms, potentially linked to NO system modulation and growth factor interactions.
Systemic Cytoprotection
Beyond organ-specific effects, BPC-157 has been studied for broader cytoprotective properties in animal models, including protection against NSAID-induced organ damage, alcohol toxicity, and surgical stress β findings that have contributed to its characterization as a “body protection compound.”
Stability and Research Characteristics
BPC-157 demonstrates notable stability in human gastric juice under experimental conditions, which has been cited as relevant to its original identification and ongoing research interest. The synthetic form used in research is a lyophilized powder, typically stored at -20Β°C to maintain stability. Its relatively small molecular weight (1419.5 Da) and defined amino acid sequence make it amenable to standard LCMS verification, allowing for straightforward purity and identity confirmation.
Research Status
BPC-157 has not received FDA approval or regulatory authorization in any jurisdiction for any indication. It remains an investigational compound with no completed human clinical trials published to date. All available efficacy data derives from in vitro studies and animal models. Researchers and institutions should note that the compound’s regulatory status varies by country.
Comparison to Related Research Compounds
| Compound | Primary Research Area | Key Mechanism | Human Trial Data |
|---|---|---|---|
| BPC-157 | Tissue repair, GI, neuroprotection | Multi-pathway (VEGF, NO, FAK) | None published |
| TB-500 (Thymosin Beta-4) | Tissue repair, wound healing | Actin sequestration, angiogenesis | Limited |
| GHK-Cu | Wound healing, skin regeneration | Copper-dependent tissue remodeling | Topical only |
Research Applications
BPC-157 is available as a research-grade peptide for in vitro and preclinical research. Current areas of scientific investigation include:
- Gastrointestinal mucosal protection mechanisms
- Tendon and ligament repair biology
- Neuroregeneration and neuroprotection models
- Angiogenesis and VEGF pathway research
- Comparative healing studies with other tissue-repair peptides
References
- Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Current Neuropharmacology. 2016;14(8):857β865. PubMed
- Sikiric P, et al. “Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract.” Current Pharmaceutical Design. 2011;17(16):1612β1632. PubMed
- Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of Applied Physiology. 2011;110(3):774β780. PubMed
- Tvrdeic A, et al. “BPC 157 and Healing of Tibia Fracture in Rats.” Journal of Physiology and Pharmacology. 2020;71(5). PubMed
- Sikiric P, et al. “Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157.” Current Pharmaceutical Design. 2013;19(1):76β83. PubMed
- Hsieh MJ, et al. “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.” Journal of Molecular Medicine. 2017;95(3):323β333. PubMed
Pure Research Peptides LLC supplies research-grade BPC-157 (third-party verified purity β₯99%) with Certificate of Analysis documentation. All products are intended for laboratory and research use only.